Digital Therapeutic (DTx) Market by Application (Prediabetes, Nutrition, Care, Diabetes, CVD, CNS, CRD, MSD, GI, Substance Abuse, Rehabilitation), Sales Channel (B2C, Patient, Caregiver, B2B, Providers, Payer, Employer, Pharma) - Global forecasts to 2025

デジタル治療(DTx)の世界市場予測:用途別(前糖尿病、栄養、ケア、糖尿病、CVD、CNS、CRD、MSD、GI、薬物乱用、リハビリテーション)、販売経路別(B2C、患者、介護者、B2B、プロバイダー、支払者、雇用者、製薬)

◆タイトル:Digital Therapeutic (DTx) Market by Application (Prediabetes, Nutrition, Care, Diabetes, CVD, CNS, CRD, MSD, GI, Substance Abuse, Rehabilitation), Sales Channel (B2C, Patient, Caregiver, B2B, Providers, Payer, Employer, Pharma) - Global forecasts to 2025
◆商品コード:HIT 4407
◆調査・発行会社:MarketsandMarkets
◆発行日:2020年3月30日
◆ページ数:166
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:ヘルスケア
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD5,650 ⇒換算¥593,250見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥698,250見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥855,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

MarketsandMarkets社はデジタル治療(DTx)の世界市場が、2020年21億ドルから2025年69億ドルまで、年平均26.7%成長すると予測しています。本調査レポートでは、デジタル治療(DTx)の世界市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場動向、販売経路別(B2C、B2B)分析、用途別(治療/ケア、予防)分析、地域別分析、競争状況、企業概要などを含め、次の構成でお届け致します。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場動向
・デジタル治療(DTx)の世界市場:販売経路別(B2C、B2B)
・デジタル治療(DTx)の世界市場:用途別(治療/ケア、予防)
・デジタル治療(DTx)の世界市場:地域別
・競争状況
・企業概要

“Growing incidence of preventable chronic diseases and the need to control healthcare costs are the key factors driving the growth of the digital therapeutics market.”
The global digital therapeutics market is projected to reach USD 6.9 billion by 2025 from USD 2.1 billion in 2020, at a CAGR of 26.7% during the forecast period. Growth in this market is mainly driven by the growing incidence of preventable chronic diseases, the need to control healthcare costs, and rising investments in digital therapeutics. On the other hand, a lack of awareness and access to digital therapeutics programs in developing countries, resistance from traditional healthcare providers, and unstable payment models are challenging the growth of this market.

“Treatment/care-related applications segment accounted for the largest share of the digital therapeutics market in 2019”
Based on application, the digital therapeutics market is segmented into preventive and treatment/care-related applications. Rising healthcare costs, the growing prevalence of chronic diseases, and the ability of digital therapeutics to provide cost-effective solutions are some factors responsible for driving the market for treatment/care-related digital therapeutics applications.

“Diabetes segment is expected to dominate the market”
Based on the type of treatment/care-related application, the digital therapeutics market is further segmented into diabetes, CNS disorders, chronic respiratory diseases, musculoskeletal disorders, cardiovascular diseases, smoking cessation, medication adherence, gastrointestinal disorders, substance use disorders & addiction management, rehabilitation & patient care, and other treatment/care-related applications. The diabetes segment accounted for the largest share of the digital therapeutics market. The large share of this segment is attributed to the growing prevalence of diabetes across the globe. In addition, government initiatives to reduce the burden of diabetes using digital health are responsible for the large share of this segment.

“B2B segment is expected to grow at the highest CAGR during the forecast period.”
Based on the sales channel, the digital therapeutics market is segmented into business-to-customer (B2C) and business-to-business (B2B). The B2B segment is the largest and fastest-growing segment of the digital therapeutics market. The high preference of pharmaceutical companies to integrate digital therapeutics with their drug products to offer adherence services is a key factor driving the growth of this segment. Furthermore, rising awareness among payers, employers, and providers about the benefits of digital therapeutics has also supported the market growth.

“North America to be the largest and the fastest-growing regional market”
North America, which comprises the US and Canada, forms the largest market for digital therapeutics. The US is home to a plethora of digital therapeutics start-ups. In addition, government initiatives to support technological advancements, improvements in the reimbursement structure for digital therapeutics, and the increasing investments in digital therapeutics are responsible for the high growth of digital therapeutics in North America.

The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 (50%), Tier 2 (30%), and Tier 3 (20%)
• By Designation: C-level (75%), D-level (15%), and Others (10%)
• By Region: North America (70%), Europe (20%), APAC (7%), and the RoW (3%)

List of Companies Profiled in the Report
• Noom (US)
• Livongo Health (US)
• Omada Health (US)
• WellDoc (US)
• Pear Therapeutics (US)
• Proteus Digital Health (US)
• Propeller Health (US)
• Akili Interactive Labs (US)
• Better Therapeutics (US)
• Happify (US)
• Kaia Health (Germany)
• Mango Health (US)
• Click Therapeutics (US)
• Canary Health (US)
• Wellthy Therapeutics (India)
• Cognoa (US)
• Ayogo Health (Canada)
• Mindstrong Health (US)
• 2Morrow (US)
• Ginger (US)

Research Coverage:
This report provides a study of the digital therapeutics market. It aims at estimating the size and future growth potential of the market across different segments, such as sales channel, application, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of revenue numbers for the overall digital therapeutics market and its subsegments. This report will also help stakeholders understand the competitive landscape, gain insights to position their business, and make suitable go-to-market strategies. It will also enable stakeholders to gauge the pulse of the market and provide them with information on the key market drivers, restraints, challenges, and opportunities.

【レポートの目次】

1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 MARKETS COVERED
1.2.2 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS
1.6 LIMITATIONS

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Approach one: revenue mapping-based estimation
2.2.1.2 Approach two: buyer adoption-based estimation
2.2.2 TOP DOWN APPROACH: PENETRATION RATE BASED MARKET SIZE ESTIMATION
2.2.3 GROWTH FORECAST
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 MARKET PLAYER RANKING
2.5 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 DIGITAL THERAPEUTICS MARKET OVERVIEW
4.2 DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2025
4.3 B2B SALES CHANNEL MARKET SHARE, BY BUYER & REGION (2019)
4.4 DIGITAL THERAPEUTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing incidence of preventable chronic diseases
5.2.1.2 Rising focus on preventive healthcare
5.2.1.3 Need to control healthcare costs
5.2.1.4 Significant increase in venture capital investments
5.2.1.5 Benefits of digital therapeutics
5.2.1.5.1 Ability to induce behavioral change
5.2.1.5.2 Improved drug adherence
5.2.1.5.3 Patient convenience and user-friendliness
5.2.2 RESTRAINTS
5.2.2.1 Patient data privacy concerns
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging markets
5.2.3.2 Large undiagnosed and untreated population
5.2.3.3 Unexplored therapeutic applications
5.2.4 CHALLENGES
5.2.4.1 Unstable payment models
5.2.4.2 Reluctance among patients to adopt digital therapeutics
5.2.4.3 Lack of awareness and access to digital therapeutics programs in developing countries
5.2.4.4 Resistance from traditional healthcare providers

6 DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL
6.1 INTRODUCTION
6.2 B2B
6.2.1 PAYERS
6.2.1.1 Payers hold the highest share of the market, by B2B sales
6.2.2 EMPLOYERS
6.2.2.1 Importance of employee health management is propelling the adoption of digital therapeutics among employers
6.2.3 PHARMACEUTICAL COMPANIES
6.2.3.1 Cross-industry collaboration between digital therapeutics start-ups and pharmaceutical companies will drive market growth
6.2.4 PROVIDERS
6.2.4.1 Potential for better patient management and cost-reductions are driving demand for digital therapeutics among providers
6.2.5 OTHER BUYERS
6.3 B2C
6.3.1 CAREGIVERS
6.3.1.1 Ease of managing health conditions has driven demand for solutions among caregivers
6.3.2 PATIENTS
6.3.2.1 Awareness about preventive health among patients will drive the growth of this segment

7 DIGITAL THERAPEUTICS MARKET, BY APPLICATION
7.1 INTRODUCTION
7.2 TREATMENT/CARE-RELATED APPLICATIONS
7.2.1 DIABETES
7.2.1.1 Growing prevalence of diabetes drives market growth
7.2.2 CENTRAL NERVOUS SYSTEM DISORDERS
7.2.2.1 Potential benefits of digital therapeutics in CNS disorder management have driven the development of solutions
7.2.3 SMOKING CESSATION
7.2.3.1 Focus on providing clinically validated, effective mobile applications to help quit smoking drives market growth
7.2.4 CHRONIC RESPIRATORY DISEASES
7.2.4.1 Growing prevalence of COPD and asthma is responsible for market growth in this segment
7.2.5 MUSCULOSKELETAL DISORDERS
7.2.5.1 Potential of digital therapeutics in better pain management to drive the adoption of these solutions among end users
7.2.6 CARDIOVASCULAR DISEASES
7.2.6.1 Increasing care cost of CVD to drive the need for digital therapeutics solutions
7.2.7 MEDICATION ADHERENCE
7.2.7.1 Need to drive medication adherence rates have propelled the demand for effective solutions
7.2.8 GASTROINTESTINAL DISORDERS
7.2.8.1 Availability of mobile applications for the management of GI conditions to drive the market growth
7.2.9 REHABILITATION & PATIENT CARE
7.2.9.1 Benefits of digital therapeutics have induced startups to develop platforms for patient care
7.2.10 SUBSTANCE USE DISORDERS & ADDICTION MANAGEMENT
7.2.10.1 Potential to improve the efficiency of behavioral interventions are encouraging market growth
7.2.11 OTHER TREATMENT/CARE-RELATED APPLICATIONS
7.3 PREVENTIVE APPLICATIONS
7.3.1 PREDIABETES
7.3.1.1 Influx of startups to provide effective prevention against prediabetes drives the growth of this segment
7.3.2 OBESITY
7.3.2.1 Availability of cost-effective solutions for obesity management propels the growth of this segment
7.3.3 NUTRITION
7.3.3.1 Importance of nutrition in preventing a wide range of ailments has driven demand for digital therapeutic solutions
7.3.4 LIFESTYLE MANAGEMENT
7.3.4.1 Ability of digital therapeutics solutions to induce positive behavioral changes has contributed to rise in demand
7.3.5 OTHER PREVENTIVE APPLICATIONS

8 DIGITAL THERAPEUTICS MARKET, BY REGION
8.1 INTRODUCTION
8.2 NORTH AMERICA
8.2.1 US
8.2.1.1 Major digital therapeutics start-ups are based out of the US, which has greatly supported access to solutions
8.2.2 CANADA
8.2.2.1 Efforts are being taken by the Canadian government to support digital therapeutics
8.3 EUROPE
8.3.1 GERMANY
8.3.1.1 Germany accounted for the largest share of the digital therapeutics market in Europe
8.3.2 UK
8.3.2.1 Well-established healthcare system and government support will propel the growth of the market
8.3.3 FRANCE
8.3.3.1 Growing healthcare expenditure and favorable health insurance system to support market growth in France
8.3.4 SPAIN
8.3.4.1 Initiatives by emerging digital therapeutics startups are supporting market growth
8.3.5 ITALY
8.3.5.1 Need for alternative and effective treatment to drive the market growth in coming years
8.3.6 REST OF EUROPE
8.4 ASIA PACIFIC
8.4.1 JAPAN
8.4.1.1 Rising diabetes incidence and collaborations between stakeholders are indicators of market growth in Japan
8.4.2 CHINA
8.4.2.1 Growing geriatric population and incidence of chronic conditions will drive demand for digital therapeutics in China
8.4.3 INDIA
8.4.3.1 Rising chronic disease incidence and the need for better disease management drive market growth
8.4.4 REST OF APAC
8.5 REST OF THE WORLD
8.5.1 RISING BURDEN ON HEALTHCARE SYSTEMS DRIVES DEMAND FOR ALTERNATIVE, COST-EFFECTIVE THERAPIES IN THE ROW

9 COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 MARKET RANKING ANALYSIS, 2019
9.3 COMPETITIVE LEADERSHIP MAPPING
9.3.1 VISIONARY LEADERS
9.3.2 DYNAMIC DIFFERENTIATORS
9.3.3 INNOVATORS
9.3.4 EMERGING COMPANIES
9.4 COMPETITIVE SITUATION AND TRENDS
9.4.1 PRODUCT LAUNCHES
9.4.2 EXPANSIONS
9.4.3 PARTNERSHIPS, AGREEMENTS & COLLABORATIONS

10 COMPANY PROFILES
10.1 NOOM
10.1.1 BUSINESS OVERVIEW
10.1.2 PRODUCTS OFFERED
10.1.3 RECENT DEVELOPMENTS
10.1.4 MNM VIEW
10.2 LIVONGO HEALTH
10.2.1 BUSINESS OVERVIEW
10.2.2 PRODUCTS OFFERED
10.2.3 RECENT DEVELOPMENTS
10.2.4 MNM VIEW
10.3 OMADA HEALTH
10.3.1 BUSINESS OVERVIEW
10.3.2 PRODUCTS OFFERED
10.3.3 RECENT DEVELOPMENTS
10.3.4 MNM VIEW
10.4 PROTEUS DIGITAL HEALTH
10.4.1 BUSINESS OVERVIEW
10.4.2 PRODUCTS OFFERED
10.4.3 RECENT DEVELOPMENTS
10.5 WELLDOC
10.5.1 BUSINESS OVERVIEW
10.5.2 PRODUCTS OFFERED
10.5.3 RECENT DEVELOPMENTS
10.6 GINGER
10.6.1 BUSINESS OVERVIEW
10.6.2 PRODUCTS OFFERED
10.7 PROPELLER HEALTH
10.7.1 BUSINESS OVERVIEW
10.7.2 PRODUCTS OFFERED
10.8 2MORROW
10.8.1 BUSINESS OVERVIEW
10.8.2 PRODUCTS OFFERED
10.8.3 RECENT DEVELOPMENTS
10.9 CANARY HEALTH
10.9.1 BUSINESS OVERVIEW
10.9.2 PRODUCTS OFFERED
10.9.3 RECENT DEVELOPMENTS
10.10 MANGO HEALTH INC.
10.10.1 BUSINESS OVERVIEW
10.10.2 PRODUCTS OFFERED
10.10.3 RECENT DEVELOPMENTS
10.11 CLICK THERAPEUTICS
10.11.1 BUSINESS OVERVIEW
10.11.2 PRODUCTS OFFERED
10.11.3 RECENT DEVELOPMENTS
10.12 PEAR THERAPEUTICS
10.12.1 BUSINESS OVERVIEW
10.12.2 PRODUCTS & SERVICES OFFERED
10.12.3 RECENT DEVELOPMENTS
10.13 AKILI INTERACTIVE LABS
10.13.1 BUSINESS OVERVIEW
10.13.2 PRODUCTS OFFERED
10.13.3 RECENT DEVELOPMENTS
10.14 WELLTHY THERAPEUTICS
10.14.1 BUSINESS OVERVIEW
10.14.2 PRODUCTS OFFERED
10.14.3 RECENT DEVELOPMENTS
10.15 COGNOA
10.15.1 BUSINESS OVERVIEW
10.15.2 PRODUCTS OFFERED
10.15.3 RECENT DEVELOPMENTS
10.16 HAPPIFY
10.16.1 BUSINESS OVERVIEW
10.16.2 PRODUCTS OFFERED
10.16.3 RECENT DEVELOPMENTS
10.17 KAIA HEALTH
10.17.1 BUSINESS OVERVIEW
10.17.2 PRODUCTS OFFERED
10.18 AYOGO HEALTH
10.18.1 BUSINESS OVERVIEW
10.18.2 PRODUCTS OFFERED
10.18.3 RECENT DEVELOPMENTS
10.19 BETTER THERAPEUTICS
10.19.1 BUSINESS OVERVIEW
10.19.2 PRODUCTS OFFERED
10.20 MINDSTRONG HEALTH
10.20.1 BUSINESS OVERVIEW
10.20.2 PRODUCTS OFFERED

11 APPENDIX
DISCUSSION GUIDE
11.1 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
11.2 AVAILABLE CUSTOMIZATIONS
11.3 RELATED REPORTS
11.4 AUTHOR DETAILS



★調査レポート[デジタル治療(DTx)の世界市場予測:用途別(前糖尿病、栄養、ケア、糖尿病、CVD、CNS、CRD、MSD、GI、薬物乱用、リハビリテーション)、販売経路別(B2C、患者、介護者、B2B、プロバイダー、支払者、雇用者、製薬)] ( Digital Therapeutic (DTx) Market by Application (Prediabetes, Nutrition, Care, Diabetes, CVD, CNS, CRD, MSD, GI, Substance Abuse, Rehabilitation), Sales Channel (B2C, Patient, Caregiver, B2B, Providers, Payer, Employer, Pharma) - Global forecasts to 2025 / HIT 4407) 販売に関する免責事項
[デジタル治療(DTx)の世界市場予測:用途別(前糖尿病、栄養、ケア、糖尿病、CVD、CNS、CRD、MSD、GI、薬物乱用、リハビリテーション)、販売経路別(B2C、患者、介護者、B2B、プロバイダー、支払者、雇用者、製薬)] ( Digital Therapeutic (DTx) Market by Application (Prediabetes, Nutrition, Care, Diabetes, CVD, CNS, CRD, MSD, GI, Substance Abuse, Rehabilitation), Sales Channel (B2C, Patient, Caregiver, B2B, Providers, Payer, Employer, Pharma) - Global forecasts to 2025 / HIT 4407) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆